Associated Genetic Biomarkers
RAD54B is altered in 1.99% of all cancers with melanoma, colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, and glioblastoma having the greatest prevalence of alterations .
The most common alterations in RAD54B are RAD54B Mutation (0.26%), RAD54B Amplification (0.04%), RAD54B G833E (0.01%), RAD54B E638K (0.00%), and RAD54B G84R (0.00%) .
RAD54B status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RAD54B status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with RAD54B status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is RAD54B Mutation .
Niraparib is the most frequent therapy in trials with RAD54B as an inclusion criteria .
Significance of RAD54B in Diseases
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.